Working... Menu

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02052128
Recruitment Status : Unknown
Verified June 2015 by Arno Therapeutics.
Recruitment status was:  Recruiting
First Posted : January 31, 2014
Last Update Posted : June 24, 2015
Information provided by (Responsible Party):
Arno Therapeutics